Evidence map›Paper›PMID 37239262›Full record

ArticleBrain sciences2023

Trimethylamine N-Oxide Exacerbates Neuroinflammation and Motor Dysfunction in an Acute MPTP Mice Model of Parkinson's Disease.

Wei Quan, Chen-Meng Qiao, Gu-Yu Niu, Jian Wu, Li-Ping Zhao, Chun Cui, Wei-Jiang Zhao, Yan-Qin Shen

Open access · goldAbstract read
In one paragraph

Article in Brain sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trimethylamine-N-oxide: the microbial cue in immune-mediated disorders.Trends in endocrinology and metabolism: TEM · 2026
    Review
  2. Review
  3. Article
  4. Is Ergothioneine an Important Source of Plasma TrimethylamineAntioxidants (Basel, Switzerland) · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Metabolomics: a new frontier in neurodegenerative disease biomarker discovery.Metabolomics : Official journal of the Metabolomic Society · 2025
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Wei QuanDepartment of Neurodegeneration and Injury, Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Chen-Meng QiaoDepartment of Neurodegeneration and Injury, Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Gu-Yu NiuDepartment of Neurodegeneration and Injury, Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Jian WuDepartment of Neurodegeneration and Injury, Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Li-Ping ZhaoDepartment of Neurodegeneration and Injury, Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Chun CuiDepartment of Neurodegeneration and Injury, Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Wei-Jiang ZhaoDepartment of Neurodegeneration and Injury, Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Yan-Qin ShenDepartment of Neurodegeneration and Injury, Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Jiangnan University · CN

Funding

Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX22_2436The National Natural Science Foundation of China 81771384The National Natural Science Foundation of China 82171429
6 · The paper itself

Abstract

Observational studies have shown abnormal changes in trimethylamine N-oxide (TMAO) levels in the peripheral circulatory system of Parkinson's disease (PD) patients. TMAO is a gut microbiota metabolite that can cross the blood-brain barrier and is strongly related to neuroinflammation. Neuroinflammation is one of the pathological drivers of PD. Herein, we investigated the effect of TMAO on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD model mice. TMAO pretreatment was given by adding 1.5% (

Indexed as

astrocytesgut microbiota metabolitesmicroglianeuroinflammationParkinson’s diseasetrimethylamine N-oxide

Identifiers

PMID37239262
PMCPMC10216692
OpenAlexW4376278723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.